{"id":"https://openalex.org/W3097935535","doi":"https://doi.org/10.1002/cpdd.883","title":"A Phase 1 Randomized, Double\u2010Blind, Placebo\u2010Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK\u20101654 in Healthy Adults","display_name":"A Phase 1 Randomized, Double\u2010Blind, Placebo\u2010Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK\u20101654 in Healthy Adults","publication_year":2020,"publication_date":"2020-10-30","ids":{"openalex":"https://openalex.org/W3097935535","doi":"https://doi.org/10.1002/cpdd.883","mag":"3097935535","pmid":"https://pubmed.ncbi.nlm.nih.gov/33125189"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.883","doi":"https://doi.org/10.1002/cpdd.883","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.883","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014177046","display_name":"Antonios O. Aliprantis","orcid":"https://orcid.org/0000-0002-8744-2535","observed_orcids":["https://orcid.org/0000-0002-8744-2535"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Antonios O. Aliprantis","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045831371","display_name":"Dennis G. Wolford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis Wolford","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084630027","display_name":"Luzelena Caro","orcid":"https://orcid.org/0000-0003-2275-8771","observed_orcids":["https://orcid.org/0000-0003-2275-8771"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luzelena Caro","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061929848","display_name":"Brian M. Maas","orcid":"https://orcid.org/0000-0002-2410-4379","observed_orcids":["https://orcid.org/0000-0002-2410-4379"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian M. Maas","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088009307","display_name":"Hua Ma","orcid":"https://orcid.org/0000-0002-2403-1376","observed_orcids":["https://orcid.org/0000-0002-2403-1376","https://orcid.org/0009-0009-4596-2434"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hua Ma","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002900779","display_name":"Diana L. Montgomery","orcid":"https://orcid.org/0000-0002-1084-4720","observed_orcids":["https://orcid.org/0000-0002-1084-4720"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana L. Montgomery","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081196754","display_name":"Laura M. Sterling","orcid":"https://orcid.org/0009-0009-1756-7736","observed_orcids":["https://orcid.org/0009-0009-1756-7736"]},"institutions":[{"id":"https://openalex.org/I4210103107","display_name":"Celerion (United States)","ror":"https://ror.org/01gtvsc36","country_code":"US","type":"company","lineage":["https://openalex.org/I4210103107"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura M. Sterling","raw_affiliation_strings":["Celerion, Lincoln, Nebraska, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celerion, Lincoln, Nebraska, USA","institution_ids":["https://openalex.org/I4210103107"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032795065","display_name":"Allen Hunt","orcid":"https://orcid.org/0000-0002-3945-7070","observed_orcids":["https://orcid.org/0000-0002-3945-7070"]},"institutions":[{"id":"https://openalex.org/I4210103107","display_name":"Celerion (United States)","ror":"https://ror.org/01gtvsc36","country_code":"US","type":"company","lineage":["https://openalex.org/I4210103107"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allen Hunt","raw_affiliation_strings":["Celerion, Lincoln, Nebraska, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celerion, Lincoln, Nebraska, USA","institution_ids":["https://openalex.org/I4210103107"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kara S. Cox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kara S. Cox","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048700949","display_name":"Kalpit A. Vora","orcid":"https://orcid.org/0000-0001-9844-634X","observed_orcids":["https://orcid.org/0000-0001-9844-634X"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kalpit A. Vora","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004631798","display_name":"Brad A. Roadcap","orcid":"https://orcid.org/0000-0002-9292-0140","observed_orcids":["https://orcid.org/0000-0002-9292-0140"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brad A. Roadcap","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022872342","display_name":"Radha A. Railkar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Radha A. Railkar","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059168347","display_name":"Andrew Wen-Tseng Lee","orcid":"https://orcid.org/0000-0001-8032-2170","observed_orcids":["https://orcid.org/0000-0001-8032-2170"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew W. Lee","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011021512","display_name":"Selwyn Aubrey Stoch","orcid":"https://orcid.org/0000-0001-5620-7092","observed_orcids":["https://orcid.org/0000-0001-5620-7092"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Aubrey Stoch","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048221931","display_name":"Eseng Lai","orcid":"https://orcid.org/0000-0001-5141-3452","observed_orcids":["https://orcid.org/0000-0001-5141-3452"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eseng Lai","raw_affiliation_strings":["Merck & Co., Inc. Kenilworth New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Kenilworth New Jersey USA","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5048221931"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":null,"fwci":5.9695,"has_fulltext":false,"cited_by_count":69,"citation_normalized_percentile":{"value":0.97448681,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"10","issue":"5","first_page":"556","last_page":"566"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11243","display_name":"Respiratory viral infections research","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11243","display_name":"Respiratory viral infections research","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/respiratory-syncytial-virus","display_name":"respiratory syncytial virus","score":0.9589999914169312},{"id":"https://openalex.org/keywords/neutralizing-monoclonal-antibodies","display_name":"neutralizing monoclonal antibodies","score":0.906000018119812},{"id":"https://openalex.org/keywords/passive-immunization","display_name":"passive immunization","score":0.949999988079071},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9359999895095825},{"id":"https://openalex.org/keywords/antidrug-antibodies","display_name":"antidrug antibodies","score":0.722000002861023},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.7799999713897705},{"id":"https://openalex.org/keywords/palivizumab","display_name":"palivizumab","score":0.7609999775886536}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8980343341827393},{"id":"https://openalex.org/C2778644256","wikidata":"https://www.wikidata.org/wiki/Q412765","display_name":"Palivizumab","level":3,"score":0.8603996634483337},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6880121231079102},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.65384840965271},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6537337303161621},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5586602091789246},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5523015260696411},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5121302604675293},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.47353455424308777},{"id":"https://openalex.org/C2779261636","wikidata":"https://www.wikidata.org/wiki/Q7003054","display_name":"Neutralizing antibody","level":3,"score":0.4579616189002991},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.41662395000457764},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.416288822889328},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4069581925868988},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3209435045719147},{"id":"https://openalex.org/C534529494","wikidata":"https://www.wikidata.org/wiki/Q7891","display_name":"Respiratory system","level":2,"score":0.3166162371635437},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.07250067591667175},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007273","descriptor_name":"Injections, Intramuscular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012136","descriptor_name":"Respiratory Syncytial Viruses","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018357","descriptor_name":"Respiratory Syncytial Virus Infections","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057134","descriptor_name":"Antibodies, Neutralizing","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D057134","descriptor_name":"Antibodies, Neutralizing","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/cpdd.883","doi":"https://doi.org/10.1002/cpdd.883","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.883","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmid:33125189","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33125189","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W1857608076","https://openalex.org/W1969371715","https://openalex.org/W1975550815","https://openalex.org/W1981740794","https://openalex.org/W2007583880","https://openalex.org/W2058870545","https://openalex.org/W2123817481","https://openalex.org/W2125065061","https://openalex.org/W2142222220","https://openalex.org/W2148090354","https://openalex.org/W2199119140","https://openalex.org/W2207681977","https://openalex.org/W2342598352","https://openalex.org/W2535198463","https://openalex.org/W2562476421","https://openalex.org/W2606016017","https://openalex.org/W2616161485","https://openalex.org/W2727509207","https://openalex.org/W2783725776","https://openalex.org/W2785431220","https://openalex.org/W2895565258","https://openalex.org/W2919205146","https://openalex.org/W2968402652","https://openalex.org/W2968988909","https://openalex.org/W2972594574","https://openalex.org/W3045880340","https://openalex.org/W3046024889"],"related_works":["https://openalex.org/W4225368692","https://openalex.org/W2894552092","https://openalex.org/W4200312747","https://openalex.org/W2588886839","https://openalex.org/W2972594574","https://openalex.org/W4404965863","https://openalex.org/W2760520564","https://openalex.org/W2562476421","https://openalex.org/W3208943416","https://openalex.org/W2143643431"],"abstract_inverted_index":{"Respiratory":[0],"syncytial":[1],"virus":[2],"(RSV)":[3],"is":[4,50],"the":[5,45,54,67,92,186,214,220],"leading":[6],"cause":[7],"of":[8,47,91,113,174,183,193,217,222],"acute":[9],"lower":[10],"respiratory":[11],"tract":[12],"infection":[13],"and":[14,17,62,142,159,179,199],"related":[15],"morbidity":[16],"mortality":[18],"in":[19,117,161,164,225],"infants.":[20,226],"Passive":[21],"immunization":[22],"with":[23,84,157,206],"an":[24,125,135,180],"RSV-neutralizing":[25,82],"antibody":[26,49,83,145,167,170],"can":[27],"provide":[28],"rapid":[29],"protection":[30],"to":[31,53,58,108,176,197],"this":[32,37,48,96],"vulnerable":[33],"population.":[34],"Proof-of-concept":[35],"for":[36,72,219],"approach":[38],"has":[39],"been":[40],"demonstrated":[41],"by":[42],"palivizumab;":[43],"however,":[44],"use":[46],"generally":[51],"restricted":[52],"highest-risk":[55],"infants":[56],"due":[57],"monthly":[59],"dosing":[60],"requirements":[61],"its":[63],"cost.":[64],"To":[65],"address":[66],"large":[68],"unmet":[69],"medical":[70],"need":[71],"most":[73],"infants,":[74],"we":[75],"are":[76],"evaluating":[77],"MK-1654,":[78],"a":[79,110,172],"fully":[80],"human":[81],"half-life":[85,173],"extending":[86],"mutations":[87],"targeting":[88],"site":[89],"IV":[90],"fusion":[93],"protein.":[94],"In":[95],"2-part,":[97],"placebo-controlled,":[98],"double-blind,":[99],"first-in-human":[100],"study,":[101],"152":[102],"healthy":[103],"adults":[104],"were":[105,147,203],"randomized":[106],"3:1":[107],"receive":[109],"single":[111],"dose":[112,127,158],"MK-1654":[114,152,194,218],"or":[115,121,128,131],"placebo":[116],"5":[118],"cohorts":[119],"(100":[120],"300":[122],"mg":[123,133],"as":[124,134],"intramuscular":[126],"300,":[129],"1000,":[130],"3000":[132],"intravenous":[136],"dose).":[137],"Safety,":[138],"pharmacokinetics,":[139],"antidrug":[140,201],"antibodies,":[141],"RSV":[143,165,223],"serum-neutralizing":[144,166],"titers":[146],"evaluated":[148],"through":[149],"1":[150],"year.":[151],"serum":[153],"concentrations":[154],"increased":[155],"proportionally":[156],"resulted":[160],"corresponding":[162],"elevations":[163],"titers.":[168],"The":[169,189],"displayed":[171],"73":[175],"88":[177],"days":[178],"estimated":[181],"bioavailability":[182],"69%":[184],"at":[185],"300-mg":[187],"dose.":[188],"overall":[190],"safety":[191],"profile":[192],"was":[195],"similar":[196],"placebo,":[198],"treatment-emergent":[200],"antibodies":[202],"low":[204],"(2.6%)":[205],"no":[207],"associated":[208],"adverse":[209],"events.":[210],"These":[211],"data":[212],"support":[213],"continued":[215],"development":[216],"prevention":[221],"disease":[224]},"counts_by_year":[{"year":2026,"cited_by_count":11},{"year":2025,"cited_by_count":15},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":16},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2020-11-09T00:00:00"}